Guidance

Cervical screening: programme and colposcopy management

Guidelines for commissioners, screening providers and programme managers for NHS cervical screening.

From:
NHS England
Published
3 May 2010
Last updated
525 JanuarySeptember 20232024 — See all updates

Documents

1. Introduction and programme policy

Ref: PHE publications gateway number GW-1065

HTML

2. Management and referral guidelines for colposcopy

Ref: PHE publications gateway number GW-1065

HTML

3. Providing a quality colposcopy clinic

Ref: PHE publications gateway number GW-1065

HTML

4. Colposcopic diagnosis, treatment and follow up

Ref: PHE publications gateway number GW-1065

HTML

5. Management of cases relating to pregnancy, menopause, contraception and hysterectomy

Ref: PHE publication gateway number GW-1065

HTML

6. Screening and management of immunosuppressed individuals

Ref: PHE publications gateway number GW-1065

HTML

7. Job roles: lead clinician colposcopist and lead colposcopy nurse

Ref: PHE publications gateway number GW-1065

HTML

Details

This document gives guidance for commissioners, screening providers and programme managers working in and with the NHS Cervical Screening Programme.

It provides information on:

  • policy
  • management and referral guidelines for colposcopy
  • providing a quality colposcopy clinic (quality standards)
  • colposcopic diagnosis, treatment and follow up
  • management of cases relating to pregnancy, menopause, contraception and hysterectomy
  • screening and management of immunosuppressed individuals
  • job roles (lead clinician colposcopist and lead colposcopy nurse)
  • screening and colposcopy pathways (flowcharts)

Updates to this page

Published 3 May 2010
Last updated 525 JanuarySeptember 20232024 + show all updates

  1. Change note 1: Clarified that the discussion of moderate referrals with CIN1 at the MDT was discretionary and there was no requirement to do so. Change note 2: Clarified that cytology should be reviewed prior to MDT in cases of conservative management of CIN2.

  2. 4.6 change to first line.

  3. Minor text changes to chapter 3 (section 5.2). More information added to chapter 4 about management of incompletely excised CGIN (section 3.3), follow up of stage Ia1 (section 4.4) and individuals referred with low-grade cytology (section 4.6).

  4. Updated guidance in line with the introduction of primary human papillomavirus (HPV) screening in England.

  5. Published 3rd edition of guidance.

  6. First published.

Sign up for emails or print this page